GlassScriptPhysician profile
Irena Vidito
NPI 1689735227
$2,943.92
in general payments reported to CMS, 2019-2025
32 companies · $47.05 in 2025
The $47.05 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,569 · 2020: $289 · 2022: $25.21 · 2023: $13.42 · 2025: $47.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $318.36 | 2019-2020 | |
| Pfizer INC. | $313.36 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $267.60 | 2019 | |
| Janssen Biotech, INC. | $235.95 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $231.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $225.09 | 2019-2020 | |
| Celgene Corporation | $140.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.04 | 2019 | |
| Clovis Oncology, INC. | $99.95 | 2019 | |
| Genentech USA, INC. | $99.52 | 2019 | |
| Rigel Pharmaceuticals, INC. | $96.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.30 | 2019 | |
| Seagen INC. | $71.95 | 2019-2020 | |
| Exelixis INC. | $64.42 | 2019 | |
| Eisai INC. | $56.75 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $50.01 | 2019 | |
| Glaxosmithkline, LLC. | $48.55 | 2020 | |
| Emd Serono, INC. | $47.73 | 2019 | |
| Biosense Webster, INC. | $47.05 | 2025 | Qdot Micro, Carto 3 |
| Abbvie INC. | $38.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $31.40 | 2019 | |
| Csl Behring | $28.00 | 2019 | |
| Secura Bio, INC. | $27.37 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.72 | 2019 | |
| Foundation Medicine, INC. | $23.91 | 2019 | |
| Genzyme Corporation | $23.77 | 2019 | |
| Agios Pharmaceuticals, INC. | $19.93 | 2019 | |
| Shionogi INC | $19.75 | 2019 | |
| Daiichi Sankyo INC. | $18.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irena Vidito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.